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Many sexual dimorphisms that exist in the brain develop in the postnatal period. For males, 
this is when testosterone levels are minimal and anti-Müllerian hormone (AMH) is elevated. 
Testosterone requires the enzyme aromatase to undergo conversion to oestradiol to exert 
masculinising effects on the brain. Hence, the effect of AMH on aromatase was investigated.  
AMH type 2 receptor (AMHR2) null mutant mice were used, with male AMHR2-/- mice 
compared to male and female AMHR2+/+ mice. Experimental groups included perinatal, pre-
pubescent and adult mice to assess different hormonal environments. In situ hybridisation 
was utilised to assess the presence of aromatase.   
Non-radioactive in situ hybridisation was developed as a technique but remained 
unsuccessful following modifications.  
A wide variation of aromatase expression within each genotype group was observed using 
radioactive in situ hybridisation. Results indicated similar levels of aromatase between the 
male AMHR2+/+ and AMHR2-/- mice. This suggests that the role of AMH could be 
independent from aromatase. To confirm this, larger sample sizes will be used so statistical 
analysis could be performed. Location of AMH intracellular signalling molecules could be 
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1. Literature Review 
1.1 Overview 
Sexual dimorphisms are the differences that exist between men and women. They include 
variations in brain size and structure (1). Testosterone is known to mediate many of the 
masculinising effects on brain development, but only after conversion to oestradiol by the 
enzyme aromatase (2). Although testosterone has a brief elevation in the foetal and postnatal 
stage, it is essentially absent in childhood until puberty begins (3). Instead, the main gonadal 
hormone present in boys is anti-Müllerian hormone (AMH). Produced in the foetal testes, it 
prevents the development of the Müllerian duct which is the precursor to the female upper 
reproductive tract (4). This was thought to be the only male function of AMH until recently, 
when AMH was shown to be a hormonal regulator of male brain development (5-8) and 
behaviour (9, 10). These changes in brain structure and behaviour occurred when 
testosterone was minimal and AMH was the main gonadal hormone present. Consequently, I 
hypothesise that AMH modulates how the brain responds to the sex steroid hormones by 




1.2 Brain Development 
1.2.1 Sexual Dimorphism and Differentiation 
The human brain is sexually dimorphic, with differences in structure and function. A clear 
difference in brain function can be seen when abnormalities occur; gender distinctions are 
pronounced in mental health across age groups and cultures (11). Women more commonly 
have disorders related to mood and anxiety, whereas men have more substance and 
behavioural disorders (11-14). Although social factors cannot be disregarded in the 
aetiology of these mental health disorders (11), the consistent gender differences suggest an 
underlying disparity.  
Structural differences are evident since early development, with 4 year old males on average 
having a cerebral volume that is 9% larger than 4 year old females (1). This divergence 
continues throughout adolescence into adulthood (1), and a dimorphism presents in various 
brain areas. For example, in terms of cortical volume relative to cerebrum size (15), the right 
motor and somatosensory cortex (16) and Broca’s area, an important area for speech 
production (17) are all likely to be larger in women. Men have a greater proportion of white 
matter in their cerebral volume (15) and a larger amygdala and hypothalamus (15). These 
areas that have a high degree of sexual dimorphism are also the areas with high levels of sex 
steroid receptors during development, indicating a possible mechanism of differentiation 
(15).  
The historical view of neural sexual differentiation is that gonadal steroids act early in 
development to cause changes in anatomy, sexual behaviour and gonadotropin secretion 
pattern (18).  A landmark paper in 1959 (19) showed that giving testosterone to female 
guinea pigs during a neonatal sensitive phase lead to masculinised mating behaviour that 
was permanent, and increased sensitivity to testosterone in adulthood. From this, the 
organisation/activational hypothesis of sexual differentiation was developed, which states 
that gonadal steroids change neural organisation during a perinatal sensitive period to alter 
the adult response to hormones (20, 21). In addition, this process leads to brain 
masculinisation for males, whereas female brain development is seen as a default pathway 
(18). Although developments to this hypothesis have been proposed (18), the original idea is 
still an important concept in sexual differentiation (22).  
Another concept which ties in with sexual differentiation is the aromatisation hypothesis, 
proposed by Naftolin et al. in 1975 (23). Aromatase is the enzyme that synthesises local 
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oestrogens from circulating androgens (2). The hypothesis states that this function mediates 
the masculinising effects on brain development and function (2). This was first realised 
when newborn female rats were given testosterone in an attempt to masculinise their brains, 
and oestradiol was used as a control. In fact, the oestradiol turned out to be more effective 
(18) whereas no effect occurred when dihydrotestosterone (DHT, binds to testosterone 
receptors but is unable to be aromatised) was given (24). The timing of aromatase 
expression in rats also corresponds with its perinatal sensitive period, said to occur between 
gestational day 18 to postnatal day 11 (25). Aromatase mRNA expression is widespread in 
the rat brain (of both sexes) at gestational day 18, in parallel with serum testosterone (26, 
27). This gives a chronological link between steroid release from the gonads, and the 
capacity for testosterone to be converted to oestradiol in the male brain. The presence of 
aromatase suggests that although oestrogen is typically regarded as a female hormone, in 
this instance it is the factor leading to normal male brain development.  
1.2.2 Steroid Receptor Expression  
Androgen and oestrogen receptors are found throughout the brain with no clear sexual 
dimorphisms in rats and mice (28, 29). Oestrogen receptors are commonly found at high 
levels in areas related to gonadotropin release and sexual behaviours while androgen 
receptors are found in motor control regions and cranial nerve nuclei (28, 30). These areas 
containing high numbers of oestrogen receptors are regions commonly studied for evidence 
of sexual dimorphism in the mouse brain. For example, the bed nucleus of the stria 
terminalis (BNST) has a sexual dimorphism in its cell number and volume by 9 days old 
(31), increasing to 35% greater in males than females by adulthood (32).  
The absence of sexual dimorphism in receptor distribution, but a sexual dimorphism in brain 
structure indicates that the structural differences could depend on factors other than 
oestrogens and androgens. Commonly stated hypotheses are alterations in steroid receptor 
binding, transcription factors activated by such binding, or an interaction between the ratio 
of androgen to oestrogen receptor binding. There is also the intriguing new proposition that 
other gonadal hormones may be involved (6-9).  
1.2.3 Oestrogen in the Brain  
Oestrogens are present in females in three forms: oestrone, oestradiol and oestriol. At 
reproductive age, oestradiol (the most potent) is the major occurring oestrogen (33). 
However, early female development occurs in a low oestrogen environment with the ovaries 
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being non-steroidal until puberty. Any oestrogen present in a female foetus will be from the 
adrenal glands, the mother or male littermates (34).  
As male-typical brains develop in the presence of oestrogens (according to the aromatisation 
hypothesis), this leads to the idea that female-typical brains develop in an oestrogen free 
environment. Alpha-fetoprotein (AFP) fulfils this role by actively protecting the female 
brain from adrenal or external oestrogens from the mother or male littermates (35). AFP is a 
plasma protein produced in the foetus which readily binds circulating oestradiol in rats and 
mice (35). Female mice that do not express AFP have male-like brain anatomy, abnormal 
sexual behaviour and infertility (34) which is rescued by aromatase inhibition during 
gestation (36). This shows that the presence of oestrogen without its binding protein in a 
developing female leads to some male-typical features, while the absence of oestrogen 
permits normal female development.  
To expand on this, oestradiol has been demonstrated to have direct masculinising effects on 
the developing female brain. Female mice given oestradiol on the day of birth have male-
like numbers of cells in the BNST (32). Using oestrogen receptor agonists also increased 
cell numbers, but not to the same level as oestradiol (32). Oestradiol administered to 
neonatal female mice also lead to the development of male-like numbers and projection 
pattern of aromatase expressing neurons (37). Here we see evidence of a classically ‘female’ 
hormone causing typical male dimorphisms. In addition to anatomical changes, the 
oestradiol treated newborn female mice also have altered behaviour. They had male-like 
territorial behaviour and urine deposition pattern (37) while they had suppressed female 
sexual behaviours, actively rejecting mounts (37, 38). Overall, the presence of oestradiol in 
the perinatal phase for female mice appears to support the development of many male-
typical characteristics.  
However, the idea that female sexual differentiation occurs in the absence of sex hormones 
has been challenged by Bakker and Baum. Their hypothesis states that after birth, oestradiol 
acts as a feminising agent on female brains, when α-fetoprotein expression is decreasing, 
and the ovaries are starting to function and produce oestrogens (34). This was supported by 
a study that showed female aromatase knockout mice in adulthood had deficits in 
reproductive behaviours such as odour preference and lordosis behaviour, indicating 
oestradiol was needed in some capacity for normal female behaviour to develop (39). This 
dual action hypothesis for oestradiol is not mutually exclusive with the aromatisation 
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hypothesis, the former acting between birth and puberty and the latter acting during prenatal 
development. It has been shown that for the BNST, oestradiol has masculinising effects 
perinatally, and demasculinising effects during puberty (40). This is a fascinating concept of 
a chronological switch for oestrogen, acting initially to produce male-typical development 
and then mediating normal female function.  
1.2.4 Testosterone in the Brain 
The role of testosterone in brain development is complex, as it can act via androgen 
receptors, or after conversion to oestradiol via oestrogen receptors (41). Castrated animals 
given testosterone supplementation are commonly studied to investigate the effects on brain 
structures or behaviour (19, 42-45). However, interpretation of these studies can be 
problematic; it is unclear whether the results are from the action of testosterone or following 
its conversion to oestrogen. An alternate study design is to use dihydrotestosterone as it is 
unable to be aromatised, restricting its effects to the androgen receptors only (24, 46). The 
use of selective aromatase inhibitors also allows for endogenous androgenic effects, but 
prevents any new formation of oestradiol (47). The two latter experimental designs also 
have the benefit of not affecting the actions of other endocrine products from the testes.  
The castration method was proved inadequate when the sexual dimorphism in the 
posterodorsal medial amygdala (MePD) was investigated. The MePD is 65% larger in adult 
male than female rats, with castrated males having volumes equal to those of females (42). 
Females and castrated males given testosterone supplementation had similar MePD volumes 
to normal males (42), but when this was repeated with separate treatment groups of 
oestradiol and dihydrotestosterone, only oestradiol had an effect on MePD volume (48). 
This shows that the initial discovery of testosterone being responsible for the difference in 
MePD volume was incorrect, and in truth it was the action of oestradiol.  
The use of DHT in testosterone related studies also allowed for investigation into whether 
testosterone acts on androgen or oestrogen receptors to facilitate male brain development. 
Female rats given DHT in utero and postnatally were compared against non-treated females 
at adulthood. There was little difference in their ovarian morphology and sexual behaviour 
(24). In addition, when newborn rats were given either DHT or testosterone, the DHT had 
no effect on lordosis (female sexual receptivity) behaviour. Testosterone inhibited lordosis 
behaviour almost completely (49). This indicates that the testosterone inhibition was likely 
due to conversion to oestradiol, as the androgen DHT had no effect on female-typical sexual 
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behaviour. The identification of the exact steroid hormone that is involved in these 
behaviours is a definite advantage for studies using this selection of testosterone, oestradiol 
and DHT. The lack of this choice in many earlier studies makes their results difficult to 
construe. The results from castration studies are also confounded by the fact that testes do 





1.3.1 AMH and Sexual Development 
AMH is a member of the Transforming Growth Factor β (TGFβ) superfamily of growth and 
differentiation factors (51). It is another gonadal hormone that acts to facilitate male 
reproductive development. It initiates its response in cells by binding to its Type II receptor, 
which incorporates the Type 1 receptor. Phosphorylation of intracellular signalling 
molecules Smad 1, 5 or 8 occur, which translocate to the nucleus to regulate gene 
transcription (52, 53). The gonads in the embryo remain undifferentiated up to the 7th week 
of gestation, at which AMH begins to be expressed from the Sertoli cells of the testes (4). 
AMH acts to cause the Müllerian duct (the precursor to the female upper reproductive tract) 
to regress by the 8th and 9th week of gestation, via apoptosis and epithelial-mesenchymal 
transition (4).  
The regression of the Müllerian duct in males is essential to a functional reproductive tract. 
AMH-/- male mice develop as pseudohermaphrodites, with both male and female 
reproductive tracts superimposed on each other (54). Although they can still make viable 
sperm it is anatomically blocked from exiting the male normally, regurgitating into their 
own hypoplastic uterus and seminal vesicles (54). Female mice over-expressing AMH have 
no uterus nor uterine tubes, a blind vagina and no ovaries by adulthood (55). Therefore, the 
presence of AMH in males and the absence of it in females is required for fertility.  
1.3.2 AMH Levels  
AMH is the major gonadal hormone produced by boys until puberty. At birth, levels are 
comparatively low (~150pmol/L) in human boys (56). After a brief rise at 6 months, levels 
are maintained throughout childhood (~700pmol/L), declining only slightly with age. (56). 
A sudden decrease occurs once they begin puberty and by the time boys reach their middle 
stage of pubertal development, their levels are reduced to adult male levels (56). Here they  
start to overlap with female levels, which after being minimal at birth have had a minor rise 
throughout childhood and puberty (57). Prior to puberty, AMH levels are at least 10 times 
higher in boys than girls (57). There is currently no explanation for why it should be raised 
in boys for such a long time as its function in regressing the Müllerian duct has clearly 
finished.  
Concurrently, as AMH is declining in puberty in boys, testosterone is rising (56) (Figure 








Figure 1.3.2.1: Serum AMH and Testosterone in human boys and mice. Measurements of serum AMH 
and testosterone in human boys and mice at chronological ages, adapted from Al-Attar et al and 
Aksglaede et al (30, 56). The black brackets show the approximate start of puberty (58, 59). There is a 
gradual decrease of AMH as puberty is reached, and a distinct increase in testosterone. The main 









surge (8nmol/L), testosterone levels stay low throughout childhood (below 1nmol/l) (3). As 
puberty begins, the levels begin to rise and reach a mean of 17nmol/L in 16 year old boys. 
This pattern shows that in boys, AMH is high and testosterone is low, and after puberty the 
reverse occurs. This makes AMH the predominant gonadal hormone present in boys in their 
early development. For girls, both AMH and testosterone are low throughout childhood and 
puberty (3). Therefore AMH is sexually dimorphic.  
Mouse models have shown a similar pattern, although they have their ‘mini puberty’ at the 
time of birth (60). Instead of AMH levels increasing during the first year of life, male mice 
have elevated levels to 6 days of age, which decreases significantly from day 7 to day 13 
(30). As it is in humans, when puberty is underway in the mouse AMH levels are low and 
testosterone levels are high.   
1.3.3 AMH and Brain Development 
The function of AMH regressing the Müllerian duct occurs early in development, before the 
sustained levels in childhood. Extensive brain development occurs when AMH is the main 
testicular hormone present and testosterone is minimal (Figure 1.3.3.1) (61). This presents 
the idea that AMH is a contributing factor to development of the brain.  
Sexual dimorphisms in the mouse brain have been identified in periods where AMH is high 
and testosterone is low. This can be observed in the bed nucleus of the stria terminalis 
(BNST) and the sexually dimorphic nucleus of the preoptic area (SDN). Pre-pubescent wild 
type male mice typically have 25% more neurons in their BNST compared to wild type 
female mice (puberty generally occurs after 30 days (58)). At adulthood this difference 
increases due to a combination of atrophy in the females and growth in the males, to the 
extent that adult males have double the number of neurons in the BNST compared to the 
adult females. However, the pre-pubescent AMH-/- male mice had similar numbers of BNST 
neurons to females. During puberty, the AMH-/- males underwent the male-typical increases 
of neurons (this appeared to be AMH independent) so at adulthood they no longer had 
female-like neuron numbers (Figure 1.3.3.2). But this growth did not completely correct the 
pre-pubertal difference in neurons between the knockout and wild type males. Consequently 
at adulthood, the AMH-/- male mice still had a significant reduction of neurons compared to 
the wild type male mice (6, 8). In addition, male AMH-/-  mice have female-like cerebella in 
terms of total volume, cell number and Purkinje cell size (7). These differences in cell 








Figure 1.3.3.1: Volumes of the mouse whole brain, neocortex, hippocampus and cerebellum compared to 
estimated adult volumes at chronological ages, from Chuang et al (56).There is a dramatic increase in 
volumes in all areas shown prior to 20 days (before puberty occurs). This is when AMH is the main 









Figure 1.3.3.2: Calbindin cell number in the SDN in AMH-/- and Wild type Mice, from Wittmann and 
Mclennan (6). At 20 days old the AMH-/- males have female-like cell numbers. However, after puberty 





same foetal testosterone surge, so the main difference in their hormonal milieu during 
development is the presence of AMH. From these results we can reason that AMH appears 
to be an important factor in the development of sexual dimorphism in the brain. 
1.3.4 AMH and Sexually Dimorphic Behaviour 
A number of behaviours have been found to be different in AMH-/- mice compared to their 
wild type counterparts. Male-typical exploratory behaviours can be quantified in novelty 
preference and rearing in field tests (9, 62). Male AMH-/- mice at 20 days old were found to 
have female-like preferences for novel or familiar objects (10), and also female levels of 
rearing (9).   
Behaviours more directly related to sexual function were also tested. Olfactory preference 
for male and female pheromones was tested using soiled bedding. All the experimental 
groups (adult and pre-pubertal male and female, wild type and knockout) preferred those 
belonging to the opposite sex. All groups except the male AMH-/- mice preferred to sniff the 
soiled bedding over the clean bedding (8). The preferential sniffing of female-soiled, rather 
than male-soiled bedding shows that that the male AMH-/- mice do have an interest in 
females and have a functioning olfactory system, but appear to be disinterested at the same 
time as they sniff more clean bedding. Similar to the differences in brain structures, these 
differences in behaviours were found prior to the pubertal testosterone surge. Given the male 
knockout and wild type mice have had the same foetal testosterone peak, this indicates a 
possible role for AMH in development of this behaviour. One possible mechanism is that 
AMH influences the actions of how testosterone acts on the male brain. Testosterone 
requires aromatase to undergo conversion to oestradiol to produce male-typical effects. It is 
therefore possible that aromatase is a factor influenced by AMH that leads to these changes 





1.4.1 Aromatase Expression 
Aromatase is found in discrete regions of the brain. Studies on adult rodent brains have 
revealed a distinctive pattern of aromatase activity, particularly around the hypothalamus 
and amygdala which are involved in reproductive behaviour and function (63). Aromatase 
activity was higher in males than females in almost all areas, with differences reaching 70% 
lower for females in the bed nucleus of the stria terminalis (BNST) (64). 
These areas of high aromatase expression also correlate with areas of high aromatase 
activity, such as the medial preoptic nucleus, BNST and the cortical and medial amygdala 
(64). These are areas involved in reproductive function and behaviour (63), with the BNST 
and medial amygdala in particular being shown to regulate sexual and aggressive behaviours 
(37). In addition, these areas high in aromatase overlap extensively with areas high in 
oestrogen receptors. This suggests that a local effect of the aromatase is occurring, where its 
oestradiol product can act on the same (or nearby) cells (65).  
In addition to sexual differences, there are transient differences in aromatase expression and 
activity during development. Activity and expression can be detected in an embryonic rat 
brain at day 16 (26, 27) localised to the preoptic area (26). Levels increase at embryonic 
days 18 and 20, with expression now occurring in the more typical areas of the 
hypothalamus, BNST and medial amygdala (26). Aromatase levels in males and females are 
similar prior to birth but by postnatal day 2 aromatase levels decrease and a sexual 
dimorphism is present (66). This identifies the possible age where the presence of aromatase 
may be essential for normal development. After postnatal day 2, male rats have significantly 
higher levels in the BNST and sexually dimorphic nucleus of the preoptic area (SDN), while 
females have higher levels in the medial preoptic nucleus. By postnatal day 6, many of these 
sex differences are no longer significant, but remain so in the BNST (66). This suggests that 
by 6 days of age, aromatase may have already influenced the sexual dimorphic structure in 
those areas. This gives us an indication of what time points could be valuable in examining 



















High Reference Intermediate Reference 
Hypothalamic 
structures 
 Medial Preoptic 
Nucleus 
(65, 67, 68)  Ventromedial 
nucleus 







 Bed nucleus of the 
stria terminalis 










1.4.2. Aromatase and Brain Sexual Differentiation 
As normal brain development requires aromatase to synthesise local oestrogens from 
circulating androgens (2) this places aromatase at high importance in sexual differentiation 
of the brain. There are multiple sexually dimorphic areas in rodents that contain high levels 
of aromatase (69), often in areas related to reproductive behaviours. One of these areas in 
the rat brain is the Sexually Dimorphic Nucleus (SDN), located in the medial preoptic area 
of the hypothalamus which is known for sexual function and behaviour (26, 63). 
The SDN is 2-3 times larger in male than female rats and appears to be dependent on 
aromatised testosterone (70) present during the perinatal stage (71). Perinatal administration 
of testosterone or oestrogens to female rats increased their SDN volumes (43, 71). To 
identify whether testosterone was exerting an effect only after conversion to oestradiol or in 
addition to acting as an androgen, antagonist based studies were performed. Oestrogen 
antagonists (72) and aromatase inhibitors (73) were found to reduce the SDN volume of 
male rats to female-like volumes, while an androgen antagonist had no effect (72). This 
local oestrogen synthesis by aromatase is therefore crucial in the development of male-
typical sexual dimorphisms in the brain.  
1.4.3 Aromatase and Sexual Behaviour 
The presence of aromatase in neural pathways for reproductive behaviour (37) gives an 
indication to its role in regulation sexual behaviour (63). In particular, it has been shown to 
be involved in some of the sexual behaviours that were found to be different in AMH-/- mice. 
Akin to the male AMH-/- mouse, the male aromatase knockout mouse appears to 
simultaneously prefer female odours, but also displays a significant level of disinterest for 
the pheromones of both male and female mice (74). Other changes in sexual behaviour seen 
in the aromatase knockout mouse include decreases in mounting, intromission and 
ejaculation (74-77). Similar results were found for male rats given an aromatase inhibitor 
perinatally (73, 78-81) and they also displayed a sexual preference for males over oestrous 
females (73, 78, 82, 83) . For most of these studies the critical time for aromatase to be 
inhibited was the early postnatal stage as the rats that were given aromatase inhibitor on 
those days had more significant differences compared to controls, and compared to rats that 
were only given the inhibitor while still in gestation. This is in agreement with the high 
expression of aromatase during the early postnatal stage, and gives us an indication of when 
the presence of aromatase is essential in development of normal male sexual behaviour.  
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1.4.3 Aromatase Regulation 
Aromatase itself is regulated through an androgen receptor-mediated feed-forward 
mechanism with testosterone being both the substrate and regulator (84). However, 
testosterone itself has wide ranging actions at each age group and brain regions, so 
aromatase regulation can become complex (63).  
Androgen regulation during the foetal stage is unclear (85). Hypothalamic explants from 
prenatal rats failed to increase their aromatase activity when cultured with sex steroids (86). 
In addition, castration of foetal monkeys resulted in no change in brain aromatase activity, 
with and without androgen treatment (87). There is some evidence to show that in adult rats, 
aromatase is regulated by androgens. Castrated male and female adult rats showed a 
reduction in aromatase activity and mRNA in the hypothalamic and preoptic area (HPOA) 
(68). This effect was rescued by testosterone and dihydrotestosterone treatment, but not 
oestradiol, implicating an androgen mediated mechanism (68). However, the castration 
method of these studies means that the contribution of the other gonadal hormones cannot be 
examined.  
Nevertheless, the role of androgens has also been demonstrated by other means. Adult male 
rats deficient in androgen receptors have significantly reduced brain aromatase activity, 
unaltered by castration or testosterone treatment (88). Reduced brain aromatase is also seen 
in male rats treated with an androgen antagonist compared to controls (89). Overall, 
testosterone and dihydrotestosterone stimulate aromatase activity (68) while the absence of 
androgen receptors (88) or administration of an antagonist (89) decreases aromatase activity, 
concluding that androgens are a regulator of aromatase in the adult rat brain. This means that 
the difference in basal circulating androgen levels in male and female rats also leads to a 
difference in aromatase levels (84). But male rats also have a greater response to androgen 
stimulation, shown by castrated males having higher aromatase activity and mRNA 
following a dose of DHT compared to ovariectomised females (90).  
Although testosterone has been extensively shown to regulate aromatase in the brain, AMH 
has been shown to have some effects on aromatase in the ovary. Initially, this was 
discovered when ovaries cultured in AMH developed testes-like structures and increased 
their testosterone secretion (91, 92). This has been found in the ovaries of various species 
(92, 93) but conflicting results have been found in testicular tissue (93, 94). The actions of 
AMH upon other systems have not been thoroughly investigated as of yet.  
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1.5 Study Proposal 
The aims of this study will be to determine if the levels of aromatase are different in 
aromatase knockout mice compared to their wild type counterparts.  
To investigate this, three genotypes will be used: male and female wild type mice 
(AMHR2+/+), and male AMH receptor knockout mice (AMHR2-/-). This will allow us to 
compare if the male AMHR2-/- mice have levels of aromatase more similar to wild type 
females, or males. Three age groups will be used, 2 day old mice, 20 day old mice and 42 
day old mice. This allows us to look at different hormonal environments. For wild type 
males at 2 days old, there is high testosterone, high AMH, high aromatase levels 
comparatively. Pre-pubescent 20 day old mice have low testosterone, decreasing AMH and 
low aromatase. Adult 42 day old mice have high testosterone, low AMH and low aromatase. 
Female mice at all stages have low testosterone and low AMH, and lower aromatase levels 
compared to males.  
Experimental techniques used will include non-radioactive and radioactive in situ 
hybridisation for the aromatase enzyme. Immunohistochemistry will be used for intracellular 





2.1.1 Animal tissue collection  
2% Paraformaldehyde 
100 ml dH2O and 4 g paraformaldehyde heated to 50°C 
Add 1M NaOH drop wise until clear and make up to 200 ml with 0.2M PB.  
Filter and adjust pH to 7.4 
 
30% sucrose 
30 g sucrose 
Make up to 100 ml with distilled H2O 
 
2.1.2 In situ hybridisation stock solutions 
Diethylpyrocarbonate (DEPC) treated water 
1 ml DEPC 
2000 ml dH2O 
Stir overnight and autoclave for 40 minutes to inactivate the DEPC 
 
2M Tris  
121.14 g Tris 
400 ml dH2O 
Adjust pH to 8, make up to 500 ml with dH2O, and autoclave for 20 minutes 
 
TE Buffer 
1 ml 2M Tris 
400 µl 0.5M EDTA ph8 








3M Sodium acetate 
24.6 sodium acetate anhydrous 
80 ml dH2O 
Adjust pH to 7.5 with glacial acetic acid, make up to 100 ml with dH2O and autoclave for 20 
minutes 
 
0.2M Phosphate Buffer 
160 ml 0.5M Na2HPO4.2H2O 
40 ml 0.5M NaH2PO4.H2O 
Adjust pH to 7.3 and make up to 500 ml with dH2O 
 
20 x SSC 
175.3 g NaCl 
88.2 g trisodium citrate.2H2O 
800 ml dH2O 
Adjust pH to 7 and make up to 1 L with dH2O and autoclave for 20 minutes 
 
5 x TEA 
92.8 g TEA HCl 
45 g NaCl 
900 ml dH2O 
Adjust pH to 8 and make up to 1 L with dH2O 
 
tRNA stock solution 
50 mg tRNA 
1 ml DEPC water 











7.5 g dextran sulphate 
10 ml DEPC water 
Heat to 68°C until dissolved. Cool to RT and make up volume to 15 ml with DEPC water. 
To 10 ml of this solution, add 
5 ml 100% formamide 
1 ml 3M NaCl 
100 µl 0.5M EDTA pH8 
200 µl Denhardt’s solution 
Store at -20°C until use, when 154.4 mg DTT is added 
 
Fixer for slide development 
240 g sodium thiosulphate 
600 ml tap water 
Stir to dissolve, then make up to 800 ml  
 
2.1.3 In situ hybridisation working solutions  
These are solutions made up on the day of use, sufficient for 75 slides.  
2% Paraformaldehyde 
300 ml dH2O heated to 45°C 
Add 12 g paraformaldehyde and heat up to 65°C 
Add 1M NaOH drop wise until clear and make up to 600 ml with 0.2M PB.  
Filter and adjust pH to 7.4 
 
0.5 X SSC 
30 ml 20 x SSC 
1170 ml DEPC water 
 
RNase Buffer 
166 ml 3M NaCl 
5 ml 2M Tris 




Proteinase K Solution 
600 ml RNase Buffer 
120 µl proteinase K, add just before use  
 
1 x TEA 
120 ml 5 x TEA 
480 ml DEPC water 
 
1 x TEA with acetic anhydride 
120 ml 5 x TEA 
480 ml DEPC water 
1.5 ml acetic anhydride, add just before use 
 
2 x SSC 
150 ml 20 x SSC 
Make up to 1.5 L with DEPC water 
 
Box Buffer 
18 ml 20 x SSC 
45 ml formamide 
27 ml DEPC water 
 
50% ethanol 
125 ml 100% ethanol 
125 ml DEPC water 
 
80% ethanol 
200 ml 100% ethanol 
50 ml DEPC water 
 
95% ethanol 
237.5 ml 100% ethanol 




2 x SSC (post hybridisation) 
300 ml 20 x SSC 
Make up to 3 L with dH2O 
If using radioactive labelled probes, include: 
6 ml 0.5M EDTA  
2103 µl β-mercaptoethanol 
 
0.1 x SSC (post hybridisation) 
30 ml 20 x SSC 
Make up to 3 L with dH2O 
If using radioactive labelled probes, include: 
6 ml 0.5M EDTA  
2103 µl β-mercaptoethanol 
 
0.5 x SSC (post hybridisation) 
30 ml 20 x SSC 
Make up to 1.2 L with dH2O 
 
RNase A Solution 
600 ml RNase Buffer 
1.2 ml RNase A, add just before use 
 
Buffer 1 
150 ml 2M Tris 
150 ml 3M NaCl 
2.5 L dH2O 
Adjust pH to 7.5 and make up to 3 L with dH2O 
 
Buffer 3 
75 ml 2M Tris 
49.5 ml 3M NaCl 
15.2475 g MgCl2.6H2O 
1.4 L dH2O 




1 x SSPE 
125 ml 20 x saline-sodium phosphate-EDTA  
Make up to 2.5 L with dH2O 
 
Fixer 
240 g sodium thiosulfate 
600 ml tap water 
Stir to dissolve, then make up to 800 ml with tap water 
 
2.1.4 Immunohistochemistry solutions 
0.01M Phosphate Buffer (PB) 
12.1 g Na2HPO4.2H2O 
4.06 g NaH2PO4.2H2O 
Dissolve in 5L dH2O, make up to 10 L and adjust pH to 7.2-7.4 
 
Glycine in 0.01M Phosphate Buffer 
3.8 g glycine 
500 ml 0.01M PB 
 
Primary Antibody Diluting Buffer 
0.4 g NaCl 
20 µL Polysorbate 80 
10 ml 0.01M PB 
100 mg Bovine serum albumin (Jackson Immunologicals, Pennsylvania, USA) 
 
Secondary Antibody Diluting Buffer 
10 ml 0.1M PB 
100 mg Bovine serum albumin (Jackson Immunologicals, Pennsylvania, USA) 
 
Wash Buffer 
20 g NaCl 
1 ml Polysorbate 80 
1 L 0.01M PB 
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Hydrogen Peroxide 15% 
1 tablet H2O2 urea 
1 ml dH2O 
 
Hydrogen Peroxide 1% 
67 µl H2O2 15% 




2.2 Animal tissue  
Transgenic mice with a non-functioning AMH receptor 2 (AMHR2) were used (95).    
AMHR2-/- males and AMHR2+/+ males and females were bred from AMHR2 heterozygous 
crosses. Mice had ad libitum access to water and food pellets. The room was kept at 21 ± 
2°C and 45% humidity with a 12:12 hour light/dark cycle.   
Two mice were analysed for each genotype at each age group, except the male mice for the 
2 day old group, for which there were 3 mice each. This gave a total of 20 mice. Each mouse 
was anaesthetized with ketamine (225mg/kg) and medetomidine (3mg/kg). Transcardial 
perfusion using a peristaltic pump was performed for 3 minutes using 2% paraformaldehyde 
in 0.1 M phosphate buffer (2 day mice 0.5 ml/min, 20 day mice 5 ml/min, 42 day mice 13.3 
ml/min). Brains were dissected from the mice and left in 2% PFA for post-fixation for 3 
hours, and then in 30% sucrose overnight at 4°C for cryoprotection. Brains were frozen in 





2.3 In situ hybridisation 
In situ hybridisation is a technique used to identify the location of a specific nucleic acid 
sequence (RNA or DNA) in a tissue section and determine the level of gene expression. The 
underlying principle is that the gene sequence of interest can be targeted by using 
complementary probes of RNA or DNA which will hybridise with it. These hybridised 
probes are labelled (fluorescence, radioactive labelling, or an antigen) so that they can be 
visualised.  
In situ hybridisation relies on the presence of the mRNA of interest so extensive measures 
must be taken to ensure that all steps leading up to hybridisation are as free of ribonucleases 
(RNase) as possible. The cryostat was cleaned with 70% ethanol and all equipment for tissue 
cutting was cleaned with RNase Away (Life Technologies, California, USA) before each 
use. All solutions for the procedure were made up in RNase free conditions, using diethyl 
pyrocarbonate (DEPC) treated water, and with all glassware baked at 200°C for at least 4 
hours. The protocol up to and including the hybridisation step was performed in a 
specialised RNase free fumehood and associated equipment.   
The brain area containing the bed nucleus of the stria terminalis (BNST) was sectioned at a 
thickness of 16µm in a cryostat set at -25°C to -23°C. Due to the increasing sizes of the 
brains, 36 sections were obtained from 2 day mice, 42 sections from 20 day mice and 60 
sections from 42 day mice. Serial sections were taken, alternating between sections being 
taken for immunohistochemistry, non-radioactive in situ hybridisation, and radioactive in 
situ hybridisation.  Brains from 20 day mice and 42 day mice were float mounted in dH2O 
placed in the cryostat onto Superfrost Plus slides (LabServ, Thermo Fisher Scientific, 
Massachusetts, USA), and dried at room temperature (RT) for 1.5 hours. Brains from the 2 
day mice were thaw mounted (their small size did not permit float mounting) onto 
Superfrost Plus slides, and dried at RT for 30 minutes. Slides from all tissues were kept at -




2.4 Aromatase non-radioactive in situ hybridisation 
2.4.1 Probe identification  
Using the Primer Blast tool from NIH, primer pairs were identified in the mouse CYP19 
(Aromatase) gene sequence. Possible primer pairs were chosen from the selection based on 
having less than 3 consecutive cytosines (C) or guanines (G) at the 3’ end which would 
affect binding as the C-G bond is stronger than the adenosine-tyrosine bond. Primers also 
had to cross an exon, and not be specific to any other major transcripts.  
Characteristics of the chosen primers were checked with the IDT Oligo Analyzer. Hairpins 
were checked for their temperature being less than annealing temperature, their ΔG being 
preferably between 0-2 and that less than 4-5 base pairs were matching on the hairpin. Self-
dimers and hetero-dimers had to have a ΔG less than 25% of the maximum ΔG, up to 3-5- 
base pairs matching, and no 3’ end binding to each other over 2 base pairs. From these 
selection criteria, 2 possible primers were identified and were ordered. A SP6 tag 
(AATTAGGTGACACTATAGAATAG) was added to the forward primer for the antisense 
probe and a T7 tag (TAATACGACTCACTATAGGGAGA) was added to the reverse 
primer for the sense probe.   
2.4.2 RNA extraction 
Ovaries from knockout and transgenic mice for Brain AMH were used for RNA extraction 
using the Acid guanidinium thiocyanate-phenol-chloroform extraction method (Trizole). 
The acidic solution separates RNA from the DNA and proteins.  
A mortar and pestle was cooled down using liquid nitrogen, into which the ovaries were 
placed and ground down. The powdered ovaries were put into a tube with 0.5 ml Trizole and 
mixed with a homogeniser. The tube was shaken by hand for 15 seconds with 0.1 ml 
chloroform, and then left at RT for 10 minutes. The tube was then spun in the centrifuge at 
4°C and 12000G for 5 minutes. At this point, the contents in the tube should be layered with 
proteins at the bottom, DNA in the middle and RNA at the top. The RNA layer was taken 
off by pipette, mixed with 250 µl propanol, and left overnight at -20°C. The next morning, it 
was spun in the centrifuge at 4°C and 12000G, this time for 10 minutes. Supernatant was 
pipetted off, leaving a pellet of the RNA on the bottom. Added to this pellet was 1 ml of 
75% ethanol, then it was briefly vortexed and centrifuged at 4°C and 13000G for 5 minutes. 
As much supernatant was taken off as possible, the rest was evaporated by placing it in a 
















Table 2.4.1.1 Primer sequences 
 Forward 5’ to 3’ Reverser 5’ to 3’ 
Primer 1 CGTGGATGTGTTGACCCTCA CTCCACGTCTCTCAGCGAAA 





The RNA was quantified against standard solutions on the microvolume spectrophotometer. 
Only one of the ovaries gave any substantial amount of RNA, at 103.5ng/µl. The RNA was 
treated to remove any DNase present using the Turbo DNase Kit (Life Technologies, 
California, USA) used according to manufacturer’s instructions. The RNA was stored at -
80°C.  
2.4.2 cDNA synthesis 
cDNA was synthesised from the extracted RNA using the SuperScript VILO cDNA 
Synthesis Kit (Life Technologies, California, USA). Added to 5 µl of the RNA was 9 µl 
H2O, 4 µl VILO reaction mix and 2 µl enzyme mix. This mixture was left at RT for 10 
minutes, put in a 42°C heating block for 60 minutes, 85°C for 5 minutes and then stored at   
-20°C.  
2.4.3 Polymerase Chain Reaction (PCR)  
The cDNA synthesised was then used to make the probe template. A PCR reaction was set 
up with 12.5 µl master mix (2X Reddy Mix, Thermo Fisher Scientific, Massachusetts, 
USA), 9.5 µl H2O, 0.5 µl each of the forward and reverse primers, and 2 µl cDNA. Control 
tubes used H2O instead of the cDNA. This went in a cycle of: 
1) 94°C for 2 minutes 
2) 94°C for 30 seconds 
3) 58°C for 1 minutes 
4) 72°C for 45 seconds 
5) Repeat steps 2-4 30 times 
6) 72°C for 5 minutes 
7) End at 10°C 
 
This resulted in a product for the second primer set, which was 247 base pairs. This was 
confirmed by a gel electrophoresis (Figure 2.4.4.1). The successful PCR protocol was 
repeated with 5 tubes, and the products were pooled together and kept at -20°C. The probe 
created from this PCR product is named Probe A. Purification of the PCR product was 
performed using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) according 
to manufacturer’s instructions. The product was stored on ice for 5 minutes, and then the 
concentration was checked on the microvolume spectrophotometer. This gave a mean of 








Figure 2.4.4.1: PCR products visualised on agarose 
gel. 1 = DNA ladder, 2 = Primer set 1, 3 = Primer set 
1 no template control, 4 = Primer set 2, 5 = Primer 
set 2 no template control.  Arrows show base pair size 
on ladder. Primer Set 2 has resulted in a clear 




2.4.4 DNA sequencing 
Samples were sent to Genetic Analysis Services at the University of Otago. It was confirmed 
that the primers produced were of the correct nucleotide sequence.  
2.4.5 Probe synthesis 
The digoxigenin (DIG) labelled probes were made using the DIG RNA labelling and 
detection kit (Roche Applied Science, Penzberg, Germany). Two sets of PCR products were 
used, the first from Primer 2 identified in the table (Probe A), and the second probe (Probe 
B) was designed by Dr Hollian Phillips (Department of Anatomy, University of Otago). 
Each PCR product was used to make an antisense and sense (control) probe.  
A mass of 200 ng of the PCR template was used for each probe (2.9 µl for Probe A, 2.2 µl 
for Probe B) along with 2 µl DIG RNA labelling and 2 µl 10 X transcription buffer. The 
antisense probes used 2 µl of RNA Polymerase T7 and the sense probes used 2 µl of RNA 
Polymerase SP6. All tubes were made up to 20 µl by using nuclease free water. After 
pipetting to mix, they were briefly centrifuged and incubated in 37°C heat block for 2 hours. 
Following incubation, 1 µl of DNase was added, followed by a further 15 minutes at 37°C. 
To stop the reaction, 2 µl of EDTA was used, and then 27 µl TE buffer was used to make it 
up to 50 µl. For purification, it was run through a Mini Quick Spin RNA column (Roche 
Applied Science, Penzberg, Germany). The probes were stored at -80°C until use.  
Following DIG labelling, the concentrations of the probes were checked using a dot blot. 
This process estimated the concentrations of the probes to be between 15-20 ng/µl. These 
numbers were used in calculating the probe-hybridisation buffer mixture.  
2.4.6 In situ hybridisation protocol 
2.4.7.1 Tissue preparation 
Slides were taken out of the -20°C freezer and carried on dry ice to a 55°C oven, where they 
thawed for 5 minutes. Post fixation in 2% paraformaldehyde for 5 minutes at RT was 
performed. Slides were washed in 0.5 x SSC for 5 minutes and then immersed in 2 µg/ml 
proteinase K solution for 10 minutes in order to digest the tissue sufficiently to allow for 
probe hybridisation. Three washes followed: 0.5 x SSC for 10 minutes, 1 x TEA for 3 
minutes and 1 x TEA with acetic anhydride. The acetylation occurs on the positively 
charged amino acids to prevent background binding with the negatively charged probes. 
Slides were washed twice in 2 x SSC for 2 minutes. Sections were dehydrated by immersion 
in 50% ethanol for 1 minute, 80% ethanol for 1 minute, 95% ethanol for 2 minutes, 100% 
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ethanol for 1 minute, chloroform for 5 minutes (to remove lipids), 100% ethanol for 1 
minute and 95% ethanol for 1 minute. The slides were allowed to air dry for at least 1 hour.  
2.4.7.2 Hybridisation 
Hybridisation buffer was thawed and DTT was added to give a final concentration of 
100mM. For each slide, 0.8 µl of probe and 1 µl of tRNA was needed. Each probe and 
tRNA mixture was heated at 95°C on the heat block for 3 minutes for denaturing, and then 
immediately put into ice cold hybridisation buffer (enough to make up to volume 120 µl for 
each slide) and pipetted to mix. The 120 µl was put on each slide and covered with a 
hybridisation cover slip. They were placed elevated in hybridisation boxes lined with paper 
towels soaked in box buffer to maintain humidity. The slides were incubated at 55°C for 18 
hours.  
2.4.7.3 Washing 
The slides were taken out of the oven and left in the fumehood for 5 minutes. They were 
soaked in 2 x SSC until the coverslips came off, and were washed twice in 2 x SSC for 10 
minutes. Non-specific background staining was reduced by immersion in 2% RNase A 
solution for 30 minutes. Slides were washed twice in 2 x SSC for 10 minutes, then washed 
in 0.1 x SSC in a 65°C water bath for 2 hours (solution changed halfway through). After the 
hot wash to reduce non-specific hybridisation, slides were put in 0.5 x SSC for 10 minutes, 
and twice in Buffer 1 for 5 minutes.  
2.4.7.4 Antibody labelling 
Sections were blocked with DIG blocking solution diluted 1:5 in Buffer 1 with 1% triton for 
30 minutes. They were incubated with DIG-AP antibody diluted 1:2000 in blocking solution 
at 4°C for 36-48 hours. 
Sections were washed twice in Buffer 1 for 10 minutes, and once in Buffer 3 for 10 minutes.  
2.4.7.5 Staining 
NBT/BCIP solution was applied onto slides and they were left to incubate at RT. Colour 
development time varied as specified in results.   
Slides were washed 4 times in 1 x SSPE for 30 minutes. They were rinsed in distilled H2O, 
then went through ethanol dilutions: 70%, 95% and 100% for 1 minute each. They were 
dried on a slide warmer for 1 hour at 42°C, and then coverslipped with Vectamount 
permanent mounting medium (Vector Laboratories, California, USA).  
33 
 
2.5 Aromatase radioactive in situ hybridisation 
2.5.1 Probe synthesis 
The sulphur-35 (S-35) labelled probes were made using the Riboprobe in vitro transcription 
kit (Promega, Wisconsin, USA). PCR products used for these probes were made from 
primers designed by Dr Hollian Phillips (Department of Anatomy, University of Otago) 
using protocol as per non-radioactive probes. This was the same primer set that was 
designated Probe B for non-radioactive in situ hybridisation. PCR product was visualised on 
agarose gel (Figure 2.3.2.1).  
Two µl each of ATP, GTP, CTP, RNase-free water, and 8 µl of S-35 labelled UTP were put 
in a speed vacuum on medium heat for 16 minutes. Added to this and vortexed to mix were 
2 µl each of 5 x transcription buffer, nucleotide mix, PCR product, RNase-free water, and 1 
µl of 100mM DTT. For the antisense probe 1 µl of T7 RNA polymerase was added, while 
for the sense probe 1 µl of SP6 RNA polymerase was added. For both probes, 0.5 µl of 
Rnasin ribonuclease inhibitor was added, followed by incubation at 37°C for 2 hours. After 
this incubation, 0.2 µl of DNase was added, followed by further incubation at 37°C for 15 
minutes. The reaction was stopped by 1 µl of 0.25M EDTA, and 38 µl of TEA buffer was 
added to make the probe volume up to 50 µl.  
To purify the probe, it was put through a Mini Quick Spin RNA column twice (Roche 
Applied Sciences, Penzberg, Germany). Volume was made up to 100 µl by TEA buffer, and 
the probe was kept at -80°C for a maximum time of 1 week. The incorporation of S-35 with 
the probe was measured by a scintillation counter. An incorporation of 60% was deemed 
ideal.    
2.5.2  Radioactive in situ hybridisation protocol 
2.5.2.1 Tissue preparation 
Slides were taken out of the -20°C freezer and carried on dry ice to a 55°C oven, where they 
thawed for 5 minutes. Post fixation in 2% paraformaldehyde for 5 minutes at RT was 
performed. Slides were washed in 0.5 x SSC for 5 minutes and then immersed in 2 µg/ml 
proteinase K solution for 10 minutes in order to digest the tissue sufficiently to allow for 
probe hybridisation. Three washes followed: 0.5 x SSC for 10 minutes, 1 x TEA for 3 
minutes and 1 x TEA with acetic anhydride. The acetylation occurs on the positively 
charged amino acids to prevent background binding with the negatively charged probes. 



























Figure 2.5.1.1: PCR product visualised on agarose gel. 1 = DNA 
ladder, 2 = Probe B primers, 3= no template control. Arrows 
show base pair size on ladder. Product is of the expected size of 





in 50% ethanol for 1 minute, 80% ethanol for 1 minute, 95% ethanol for 2 minutes, 100% 
ethanol for 1 minute, chloroform for 5 minutes (to remove lipids), 100% ethanol for 1 
minute and 95% ethanol for 1 minute. The slides were allowed to air dry for at least 1 hour. 
2.5.2.2 Hybridisation 
The probe was removed from the freezer and centrifuged at 4°C at 12000G for 20 minutes. 
Supernatant was poured off, and 500 µl ice cold ethanol was added. This was centrifuged 
again at 4°C at 12000G for 5 minutes. Supernatant was pipetted off, and the probe was left 
to air dry for 20 minutes. The pellet was dissolved in TE buffer, and samples taken to be 
read by the scintillation counter to ensure they were above 60,000 counts.  
For each slide, 2 µl of probe and 1 µl of tRNA was needed. Each probe and tRNA mixture 
was heated at 95°C on the heat block for 3 minutes for denaturing, and then immediately put 
into ice cold hybridisation buffer (enough to make up to volume 120 µl for each slide) and 
pipetted to mix. The 120 µl was put on each slide and covered with a hybridisation cover 
slip. They were placed elevated in hybridisation boxes lined with paper towels soaked in box 
buffer to maintain humidity. The slides were incubated at 55°C for 18 hours.  
2.5.2.3 Washing 
The slides were taken out of the oven and left in the fumehood for 5 minutes. They were 
soaked in 2 x SSC until the coverslips came off, and then were washed twice in 2 x SSC for 
10 minutes. They were then immersed in 2% RNase A solution for 30 minutes to reduce 
non-specific background staining. Slides were washed twice in 2 x SSC for 10 minutes, then 
washed in 0.1 x SSC in a 65°C water bath for 2 hours (solution changed halfway through). 
Slides were washed twice in 0.5 x SSC for 10 minutes each. They were then put through 
ethanol washes: 50%, 80%, 95% and 100% for 3 minutes each and dried overnight.  
2.5.2.4 Film development  
Slides were put into cassettes with film for 2 weeks at 4°C. After film development, the 
slides were kept at RT until emulsion.  
2.5.2.5 Emulsion 
Slides were dipped in radiographic emulsion (Ilford Nuclear Emulsion K5, Agar Scientific, 
Stansted, Essex) at 40°C, air dried vertically for 15 minutes and horizontally for 1 hour at 
RT. They were placed into slide boxes which were put into light-proof metal tins containing 
desiccant. The slides were stored at 4°C for at least 4 weeks.  
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Slides were immersed in slide developer solution (Kodak D-19 Replacement, EMS, 
Pennsylvania, USA) at 20°C for 8 minutes, agitated every minute. They were then put into 
tap water at 20°C for 30 seconds as a stop solution. This was followed by 10 minutes with 
gentle agitation in a fix solution (30% sodium thiosulfate), and finally slides were washed 
for 20 minutes in running tap water.  
Counterstaining was performed using cresyl violet. Slides were put through 10 seconds of 
70% ethanol, 95% ethanol, 70% ethanol, H2O and then 30-40 seconds in 0.1% cresyl violet 
solution. Slides were destained for 20 seconds in 100% ethanol.  
Slides were placed on a slide warmer at 42°C for 1 hour, put into xylene for 5 minutes twice 
and coverslipped using Vectamount permanent mounting medium (Vector Laboratories, 




2.6 Smad 1/5/8 Immunohistochemistry  
Immunohistochemistry is a technique based on the principle that specific antibodies bind to 
their specific antigen. This specific antigen for this procedure is phosphorylated Smad 1/5/8, 
an intracellular signalling molecule of AMH.   
2.6.1 Immunohistochemistry Protocol  
2.6.1.1 Tissue Preparation 
Brain sections were cut at 16µm at -25°C and thaw mounted onto Superfrost Plus slides 
(LabServ, Thermo Fisher Scientific, Massachusetts, USA). They were kept at -20°C until 
use, when they were thawed for 5 minutes at room temperature. They were washed twice in 
glycine in phosphate buffer for 5 minutes each, and then twice in 0.01M phosphate buffer 
(PB) for 5 minutes each. Sections were incubated with 5% Donkey serum (Sigma-Aldrich, 
Missouri, USA) diluted in primary antibody diluting buffer for 20 minutes at RT.  
2.6.1.2 Antibody labelling 
Phosphorylated Smad 1/5/8 antibody (Chemicon, Merck-Millipore, Massachusetts, USA) 
diluted at 1:100 in primary antibody diluting buffer was added to the sections, and incubated 
at 4°C overnight. Control sections were incubated with Rabbit IgG antibody (Vector 
Laboratories, California, USA) at 1:1000 dilution.  
Sections were washed 6 times in wash buffer for 5 minutes each and incubated with Donkey 
Anti-Rabbit biotinylated antibody (Jackson Immunologicals, Pennsylvania, USA) diluted at 
1:500 (concentration unknown) for 1.5 hours. They were washed 3 times in wash buffer for 
5 minutes. A 1% hydrogen peroxide solution was applied for 10 minutes, and washed in 
0.01M PB for 5 minutes.  
2.6.1.3 Staining 
Streptavidin-Biotinylated Horseradish Peroxidase complex (Amersham, GE Healthcare, 
Buckinghamshire, UK) diluted 1:100 with secondary antibody diluting buffer was applied 
for 1 hour. Sections were washed 3 times in 0.01M PB for 1 minute each. 3,3'-
Diaminobenzidine (DAB) solution (DAB substrate kit, Vector Laboratories, California, 
USA) was applied for 12 minutes and then sections were washed in tap water and distilled 
water for 5 minutes each. Glue was removed and slides were left to dry before being dipped 




3. Results  
3.1 Aromatase non-radioactive in situ hybridisation 
Initial non-radioactive in situ hybridisation was performed using a selection of brain tissue, 
with ovary and testes used as positive controls. The time needed for colour development was 
unknown, so the sections were checked every two hours up to 6 hours, then every two hours 
the following day. There was no clear positive staining initially and background staining 
could be seen at 2 hours. Most DIG labelled protocols leave colour development for 2-4 
hours, so prominent background staining at 2 hours was unexpected.   
One explanation for the high background staining was non-specific antibody binding 
causing increased detection from the NBT/BCIP colour development procedure. To 
investigate this, the in situ hybridisation protocol was repeated, from Tissue preparation 
(2.4.7.1) through to Staining (2.4.7.5) but omitting the Hybridisation (2.4.7.2) steps. 
However, slides with no antibody, anti-DIG antibody and increased antibody concentration 
all had equal levels of background staining, concentrated around the section edges and 
striatum. Five different colour development times were trialled: 1 hour, 2 hours, 4 hours, 6 
hours and overnight. This troubleshooting procedure showed that substantial background 
staining was present at 1 hour which was independent of antibody concentration. This 
suggests that it is not a problem of the anti-DIG antibody binding non-specifically.  
Several blocking procedures were trialled against endogenous phosphatases in order to 
reduce the background staining. Hydrogen chloride (HCl) and levamisole ((6S)-2,3,5,6-
tetrahydro-6-phenyl-imidazo[2,1-b]thiazole, monohydrochloride) were used, followed by 
NBT/BCIP colour development for either 10 minutes or 1 hour. The maximum time for 
development was based on the high background seen in the last experiment. Both HCl and 
levamisole were effective in blocking endogenous phosphatases compared to control at both 
time points, but HCl was more effective at 1 hour (Figure 3.1.1). The use of either solutions 
could therefore be used to improve signal-to-noise ratio.  
The effectiveness of the probes could now be investigated. Both Probe A and Probe B were 
trialled, along with no probe controls. Levamisole was included in all NBT/BCIP solutions, 
and a subset of sections had an additional HCl step applied. Some sections had their colour 
development stopped at 1 hour (Figure 3.1.2A) where light background staining could be 
observed. The remainder of the sections were stopped at 3.5 hours, at which time moderate 
background staining could be observed in many sections.  
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No clear positive staining was observed in any of the sections. There was no major colour 
difference between the antisense and sense probes, while no probe controls tended to have 
less staining. Background staining was reduced by HCl application. The difference in the 
level of staining at 1 hour between Figure 3.1.1E and Figure 3.1.2A is likely due to the full 




Figure 3.1.1: Comparison of endogenous phosphatase blocking solutions. At 10 minutes, both 
HCl (A) and levamisole (B) have greatly reduced background compared to control (C). Using 
HCl, the background staining does not increase greatly from 10 minutes (A) to 1 hour).  
However, at 1 hour, the use of levamisole still decreased background staining compared to 
control (F). The background staining for levamisole at 1 hour is similar to control at 10 




Figure 3.1.2: Tissue sections developed at 1 hour and 3.5 hours using Probe B. A and B = 
antisense probe, C = sense probe, D = antisense with HCl, E = no probe control. There is an 
increase in background staining in the antisense sections from 1 hour to 3.5 hours, which is 
delayed by the application of HCl. The no probe control at 3.5 hours has a similar amount of 
background to the antisense at 1 hour. The antisense and sense at 3.5 hours have similar levels 




3.2 Aromatase radioactive in situ hybridisation  
Radioactive in situ hybridisation revealed positive aromatase staining in all experimental 
groups. Staining in the BNST occurred in the medial division, posteromedial part and 
posterointermediate part (Figure 3.2.1). There was wide variation of staining intensity within 
each genotype (Figure 3.2.1).  At all age groups, the AMHR2-/- male mouse had staining 
intensity that was very similar with male AMHR2+/+ mice. This indicated that a level of 
aromatase expression is present in male AMHR2-/- mice.  
Radioactive in situ hybridisation was only successful for one 2 day old AMHR2+/+ female 
(Figure 3.2.1G) so valid comparisons with this group cannot be made. Staining intensity 
observed in this female was lower than the two male groups. This is consistent with previous 
reporting of aromatase expression (64). One AMHR2+/+ female was sectioned incorrectly so 
only the rostral part of the BNST was included, which had no staining (results not shown). 
The rostral to caudal staining pattern in the BNST occurred in a consistent pattern in the 
experimental animals (Figure 3.2.2). There was no staining in the rostral part, positive signal 
occurred approximately midway through the BNST in the rostral-caudal direction. This 
continued up to near the caudal end. For each section, the staining intensity was highest in 
the middle of the distribution.  
The 20 day old and 42 day old groups underwent greater than one half-life of sulfur-35 (87 
days) before emulsion coating could be performed. This was due to a delay in the supply of 
the radiographic emulsion solution. The slides developed therefore did not have adequate 
signal for comparisons to be made (Figure 3.2.4). Radiographic film images were of poor 
resolution and positive signal was difficult to identify, with significant background in some 

























Figure 3.2.1: Aromatase radioactive in situ hybridisation performed on 2 day old mice. Sections 
shown are at the same coronal level containing BNST. A, B and C are AMHR2+/+ males. D, E 
and F are AMHR2-/- males and G is an AMHR2+/+ female. The arrows show the area of the 
BNST where staining is present, STMPM = BNST medial division, posteromedial part. STMPI 
= BNST medial division, posterointermediate part. Diagram has been adapted from Paxinos 
(96). There is aromatase staining in all genotypes with variation within genotypes. C has more 
intense staining than A and B though they are all AMHR2+/+ males. There is also considerable 
overlap in staining between genotypes, D has similar staining intensity to C. Images were 












Figure 3.2.2: Aromatase radioactive in situ hybridisation performed on 2 day old mice. A to E are serial sections 
from an AMHR2-/-male mouse. F to J are serial sections from an AMHR2+/+ male mouse. Sections are separated by 
32μm and are arranged in rostral to caudal orientation from left to right. Positive staining occurs approximately 
halfway through the BNST and continues until near the caudal end. This was the pattern seen in positive staining 
throughout the BNST and was consistent throughout the genotypes, albeit with differences in staining intensity. 




































Figure 3.2.3: Radiographic films of radioactive in situ hybridisation performed on 20 
(A, B, C) and 42 day old mice (D, E, F). Arrow in A shows the positive staining in the 
region of the BNST. Radiographic films were scanned at full size, scale bar = 2mm  






























Figure 3.2.4: Radioactive in situ hybridisation performed on AMHR+/+ mice.  A is 20 days 
old and B is 42 days old. Very light positive staining can be seen. Images were captured at 
100X magnification, scale bar = 200μm 
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3.3 Smad 1/5/8/ Immunohistochemistry 
Immunohistochemistry for phosphorylated Smad 1/5/8 molecules was commenced using 
practice tissue from male AMHR2+/- mice. Positive staining was obtained in the region of 
the BNST, and the staining appeared to be located to the nucleus. This is consistent with the 
cellular location of phosphorylated Smad 1/5/8.  
The immunohistochemistry was unable to be continued due to the manufacturer’s 




























Figure 3.3.1: Phosphorylated Smad 1/5/8 immunohistochemistry performed on a 
male AMHR2+/- mouse. Nuclear staining can be seen in the region of the BNST. A 
is taken at 100X magnification, scale bar = 200µm. B is taken at 200X 




4. Discussion  
4.1 Aromatase Expression  
The results obtained from the study show that AMHR2-/- mice express aromatase at a level 
similar to AMHR2+/+ mice at 2 days old. Within each genotype there was wide variation in 
the aromatase expression in the same area of the BNST. This suggests that AMH is working 
through a pathway independent of aromatase to alter brain anatomy because aromatase 
expression appears to be unaffected by the lack of AMH.  
However, we must consider whether or not the similar aromatase expression level between 
the AMHR2+/+ and AMHR2-/- male mice is a true result. There were only 3 animals for each 
genotype, insufficient to perform statistics. Expression at 20 days old (pre-pubertal) and 42 
days old (adult) was unable to be examined properly due to insufficient staining. The mice 
with high aromatase expression could have been outliers, or they could lie in the normal 
range. Alternately, the experimental technique could be variable: the probe is not 
hybridising effectively on every section, radiographic emulsion was not applied correctly or 
positive signal was washed away during slide development. Increasing the number of 
animals in each genotype group would give us a more representative sample of the animals, 
and allow us to see if the variability in aromatase expression is a true biological effect.  
There is also the consideration of how much of an effect on brain structure a reduced 
aromatase level would cause. Testosterone levels peak at birth (60) but this has not been 
measured in the AMHR2-/- mouse. Nonetheless, 5 day old AMH-/- mice were found to have 
testosterone levels in the normal range (7). This means that the substrate for the aromatase 
enzyme is present. An adequate amount of oestradiol may still be produced to exert an effect 
on brain anatomy. AMH may need to have a major effect on aromatase for changes to occur 
in the AMHR2-/- male. The AMHR2-/- males have similar BNST neuron numbers to a 
female prior to puberty (8), but female mice have very low levels of testosterone. It is still 
possible aromatase expression is different in the AMHR2-/- mice; this would also be 




4.2 Future Investigation of Aromatase 
Beyond increasing sample size, there are other investigations that could be performed to 
validate the variability of aromatase expression seen in the present study. 
Immunohistochemistry with the aromatase enzyme was also attempted (results not shown) 
but remained unsuccessful after modifications of the protocol. Immunohistochemistry 
results alongside in situ hybridisation would have been extremely useful because the 
presence of mRNA does not always directly correlate to a final translated protein (97, 98). 
There are ‘slow’ codons in mRNA that correspond to rare tRNAs or amino acids that can 
inhibit protein production, slowing the rate of translation by six fold (99, 100). The 
aromatase amino acid sequence was found to have 177 ‘slow’ amino acids out of 503. 
Although this may not be directly applicable to murine protein translation, it presents a 
possible situation where the aromatase mRNA level may be higher than the protein product. 
This would mean that in situ hybridisation may not be reflective of what is truly happening 
in the tissue, thus immunohistochemistry would be valuable to corroborate results.  
Post-transcriptional regulation of the aromatase mRNA could be different in the AMHR2-/- 
mice. Similar levels of aromatase mRNA in AMHR2-/- and wild type mice may lead to 
different amounts of aromatase enzyme. There are many processes involved in post-
transcriptional modification and there are also micro RNA molecules (miRNAs) that repress 
gene expression. Identification of their individual function is difficult as they can regulate 
hundreds of genes each (101). But research into miRNAs is being expanded widely, and it 
can be identified using in situ hybridisation (102).  In the future it may be that the miRNA 
control of aromatase could be investigated in the AMHR-/- mice. Any possible post-




4.3 AMH Pathways 
The effect of AMH on neurons could be investigated to explore the mechanisms of the 
aromatase-independent pathway. One of the results observed in this pathway is the male-
typical increase of neuron size and number in the BNST (8). Therefore, it will be of great 
interest to see the distribution of AMH intracellular signalling molecules (phosphorylated 
Smad 1/5/8) in the BNST using immunohistochemistry. Positive staining was observed in 
the BNST in AMHR2+/- mice but was stopped as the manufacturers discontinued the 
antibody. The next step would be to find and optimise another suitable antibody.  
Immunohistochemistry would need to be performed on both AMHR2+/+ and AMHR2-/- mice 
because Smad 1/5/8 are not specific to AMH alone. They are phosphorylated by other 
members of the TGF-β superfamily (52). A reduced level of staining in the AMHR2-/- mice 
would suggest that the phosphorylated Smad 1/5/8 in the AMHR2+/+ is largely due to AMH. 
The neurons responding to AMH could then be identified. From here, we could look at the 
consequences that AMH has on the cell. Analysis of the RNA from these cells responding to 
AMH could be compared to cells not exposed to AMH. DNA microarrays could be 
performed, serial analysis of gene expression (SAGE) could be used or next generation 
sequencing techniques could be applied for the mRNA transcriptome. These techniques 
would detect which genes are being transcribed following AMH receptor activation. 
Exploring what function these genes serve would help us uncover what mechanism AMH is 




4.4 Non-radioactive in situ hybridisation methodology 
4.4.1 DIG labelled in situ hybridisation  
Radioactive in situ hybridisation provides high sensitivity in detection of low abundance 
mRNA, and was successful in this study. However, it comes with biohazard risks, long 
radiographic exposure times, probe instability and considerable expense (103-105). Non-
radioactive in situ hybridisation is a useful alternative. It costs less, has no risk of radiation 
exposure and has a much faster turnaround. In addition, it provides a higher degree of 
cellular resolution (103, 104). This would allow the precise cellular localisation of the 
aromatase mRNA. However, after several troubleshooting procedures a clearly positive 
signal was not able to be achieved using DIG labelled in situ hybridisation. 
In situ hybridisation is an extensive and complex technique. There are multiple factors that 
could have led to the failure of the DIG-labelled version of the technique. The visualisation 
process of the anti-DIG antibody followed by the NBT/BCIP colour reaction appeared to be 
too insensitive to confirm clearly positive hybridisation. Doubling concentrations or 
omitting the anti-DIG antibody caused no changes to the level of background staining. This 
suggests that the background was not due to the antibody. The application of anti-DIG 
antibody was also trialled on probe-blank sections, demonstrating that non-specific binding 
of the antibody to endogenous antigens was not occurring. Previous studies have shown that 
non-specific DIG binding is low in mammalian cells (106). Given more time, different anti-
DIG antibody concentrations could have been trialled to improve its chances of binding to 
the DIG-labelled probe.  
4.4.2 Probe hybridisation  
Probe B was shown to hybridise specifically with aromatase mRNA in radioactive in situ 
hybridisation, but Probe A was not used to conserve time and resources. It remains a 
possibility that Probe A is hybridising non-specifically with incorrect mRNA sequences, or 
not hybridising at all. Probe hybridisation can depend on its length, the temperature and the 
composition of the hybridisation buffer. A longer probe has been shown to result in more 
stable hybrids with the mRNA (107) while shorter probes diffuse more easily through the 
tissue (108) and can also use a shorter hybridisation time (109, 110). A different probe, 
binding to a different nucleotide sequence on the aromatase mRNA could be designed; 




The nucleotide sequence of Probe A may have not been ideal for the aromatase mRNA, and 
the hybridisation temperature may not have been optimal. The melt temperature (Tm - the 
temperature at which 50% of all possible hybrids are formed, and 50% still remain single 
stranded) given for Probe B on Primer-BLAST was 60°C. The hybridisation temperature 
used was 55°C, consistent with being at least 5°C lower than the Tm (109). Lower 
temperatures are widely used so it could be advantageous to trial lower hybridisation 
temperatures. The Tm is also affected by sodium chloride (NaCl) concentration (108). 
Optimisation of the NaCl concentration in the hybridisation buffer will assist in stabilising 
the hybrids formed. A doubling of the NaCl concentration was trialled in the present project 
but no improvement was observed (results not shown). This could be repeated with different 
concentrations and properly controlled to determine the optimal NaCl concentration.  
For the probe to successfully hybridise with the mRNA of interest, it needs to be able to 
diffuse through the section, and the mRNA must be unrestricted by nearby proteins. The 
current protocol includes a chloroform step in the tissue preparation phase to remove lipids, 
and a Proteinase K digestion step. Many published protocols advocate adjusting the 
temperature and duration of the Proteinase K step according to the fixation method and 
tissue type (111-113). Given the range of different protease digestion protocols that exist for 
in situ hybridisation, it would be rational to try a range of concentrations for different 
amounts of time, and at both RT and 37°C. A post-fixation step following the protein 
digestion has also been shown to be useful in preserving the mRNA present in the section 
(108).   
4.4.3 Signal amplification  
There are many options for amplification of the labelling observed, some more effective 
than others. Amplification of the target mRNA sequence (in situ PCR) is one that is 
theoretically simple. It seems ideal particularly for aromatase mRNA which has been shown 
to have a short half-life of 3 hours in bovine granulosa cells (114). In situ PCR would 
counteract the early loss of nucleic acids prior to hybridisation. These methods apply PCR 
techniques prior to in situ hybridisation. But in practice, in situ PCR often results in low 
amplification efficiency, poor reproducibility and difficulty in quantification of results (115, 
116). A similar technique which incorporates labelled nucleotides into the PCR reaction 
(eliminating the need for in situ hybridisation) has problems with incorporation of labelled 
nucleotides into non-specific PCR products, including endogenous DNA undergoing repair 
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(116). These in situ PCR methods are not widely used due to these problems, and it would 
be considered a last resort for this study.  
Amplification of the signal post-hybridisation is a more widespread method of increasing 
detection. A popular version of this is tyramide amplification. This is performed following 
DIG in situ hybridisation, with a conjugated anti-DIG horseradish peroxidase (HRP) 
antibody. Activated biotinylated tyramine is then deposited at or near the HRP site and its 
biotin sites act as further binding sites for streptavidin-biotin complexes which are then 
visualised (115, 116). This can result in an amplification factor of 5-10 fold with accurate 
localisation of signal (117). However, when signal amplification is performed, background 
is also increased so it should be used with a probe that is known to be hybridising 




4.5 Summary  
Overall, there was wide variation of aromatase expression within genotypes, and overlap in 
expression between male AMHR2+/+ and AMHR2-/- mice. This supports the concept of 
AMH acting through an aromatase-independent pathway to exert changes in brain anatomy. 
However, sample size was very small and the in situ hybridisation procedure was fully 
completed on the 2 day old mice only. Further investigations to confirm this include 
immunohistochemistry for aromatase and phosphorylated Smad 1/5/8, and genomic RNA 
studies.  
Radioactive in situ was the only technique that was successful within the time frame. Probe 
design, hybridisation temperatures, hybridisation buffer, protease digestion, and signal 
amplification could all be explored given an opportunity to further optimise the DIG in situ 
hybridisation. Some of these techniques like protease digestion and hybridisation buffer 
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